Streetbeat News

Products Services

EPOW

EPOW has received an order for 25,000 tons of energy storage materials from Xiamen HiTHIUM Energy Storage Technology Co., Ltd., marking a significant business development for the company.

Portfolio Pulse from Benzinga Newsdesk

March 07, 2024 | 2:26 pm

CYCC

CYCCP

Cyclacel Pharmaceuticals, Inc. announced that preclinical proof-of-concept data for its drug fadraciclib will be presented at the AACR Annual Meeting 2024. The data demonstrates fadraciclib's activity and antitumor effects in various cancers. Fadraciclib, a CDK2/9 inhibitor, has shown promising results in early trials for multiple cancer types. The company is currently conducting a Phase 1/2 trial for fadraciclib in advanced solid tumors and lymphoma.

Portfolio Pulse from Benzinga Newsdesk

March 07, 2024 | 2:24 pm

CELZ

Creative Medical Technology Holdings, Inc. (NASDAQ:CELZ) announced FDA authorization for CELZ-201, a cell-based therapy aimed at preventing Type 1 Diabetes Mellitus (T1D) in high-risk individuals. This marks a significant advancement in T1D prevention, showcasing CELZ's commitment to innovative healthcare solutions.

Portfolio Pulse from Benzinga Newsdesk

March 07, 2024 | 2:23 pm

OND

SOCL

SPOT

Spotify Technology SA (NYSE:SPOT) is raising its subscription fees in France in response to a new 1.2% music tax effective January 1, aimed at supporting the national music sector. This move comes after Spotify's criticism of the tax, which also affects other music streaming services like Apple Music and Google's YouTube Music. Despite a revenue increase in Q4, Spotify's earnings were below consensus. The company's strategy includes price adjustments rather than exiting the French market. Investors can access Spotify through Global X Social Media ETF (NASDAQ:SOCL) and ProShares On-Demand ETF (NYSE:OND).

Portfolio Pulse from Anusuya Lahiri

March 07, 2024 | 2:18 pm

TSLA

Tesla Inc (NASDAQ:TSLA) shares are declining, marking potentially their worst week since January due to disappointing China sales, a production halt at the Gigafactory in Germany following a suspected arson attack, and lowered analyst price targets. Tesla's China sales dropped significantly in February, with a 15.51% decrease from January and an 18.87% year-over-year decline. The Gigafactory Berlin was forced to halt production due to a power outage caused by a suspected arson attack, claimed by the Volcano Group. Analysts, including Morgan Stanley's Adam Jonas, have lowered price targets and expressed concerns over Tesla's ability to meet delivery numbers this quarter.

Portfolio Pulse from Adam Eckert

March 07, 2024 | 2:16 pm

AVGO

Broadcom Inc. (NASDAQ:AVGO) is set to release its Q1 earnings with expected earnings of $10.29 per share and projected revenue of $11.72 billion. The company recently unveiled the WatchTower Platform, an open observability solution. Broadcom's dividend yield stands at 1.56%, with a quarterly dividend of $5.25 per share. To earn a monthly dividend income of $500, an investor would need to own approximately 286 shares, valued around $386,100. The article also explains how dividend yield changes with stock price and dividend payment adjustments. AVGO shares rose 0.5% to close at $1,350.00 recently.

Portfolio Pulse from Avi Kapoor

March 07, 2024 | 2:14 pm

CYH

Community Health Systems, Inc. (CHS) has partnered with Mark Cuban Cost Plus Drug Company to purchase select pharmaceutical supplies, marking CHS as the first national healthcare system to do so. This collaboration aims to bring high-quality, lower-cost drugs to the hospital setting, starting with CHS-affiliated hospitals in Texas and Pennsylvania. The partnership coincides with the opening of Cost Plus Drugs' new drug manufacturing plant in Dallas, Texas. The initiative addresses rising pharmaceutical costs, drug shortages, pharmaceutical waste, and patient safety by offering drugs at minimal mark-up and in flexible ordering options.

Portfolio Pulse from Benzinga Newsdesk

March 07, 2024 | 2:12 pm

NUWE

Nuwellis announced results from two new clinical data analyses from the AVOID-HF trial, showing the benefits of the Aquadex system for heart failure. The analyses demonstrated that ultrafiltration therapy is statistically superior to intravenous loop diuretics in reducing heart failure events and hospitalizations. Additionally, an AI and machine learning-based model indicated that lifestyle and clinical factors are strong predictors of heart failure events.

Portfolio Pulse from Benzinga Newsdesk

March 07, 2024 | 2:10 pm

GM

RTX

Neural Propulsion Systems (NPS) has secured a $17.5 million Series B funding round led by Cota Capital, with contributions from GM Ventures and RTX Ventures. The funding will be used to develop NPS's Atomic Sensing Platform for automotive radar technology, aiming to enhance road safety and defense radar systems. The technology promises over 10 times the performance of current radar capabilities, potentially revolutionizing the $28 billion radar market.

Portfolio Pulse from Anusuya Lahiri

March 07, 2024 | 2:10 pm

LEXX

Lexaria Bioscience has engaged a Contract Research Organization to conduct its upcoming GLP-1 human pilot study. This move indicates Lexaria's commitment to advancing its research and development efforts in the medical field.

Portfolio Pulse from Benzinga Newsdesk

March 07, 2024 | 2:08 pm